An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

Cited by (1,001)

Items 201–300 of 1,001

1. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets
   Thomas B. Knudsen, Keith A. Houck, Nisha S. Sipes, Amar V. Singh, Richard Judson, Matthew T. Martin, Arthur D. Weissman, Nicole Kleinstreuer, Holly M. Mortensen, David M. Reif et al. · 2011 · Toxicology
2. EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
   Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Richard E. Cutler, Ryan Fong, Roel Peter Funke, Steven B. Gendreau, Yong D. Kim, Nicole Miller, John R. Woolfrey et al. · 2008 · Clinical Cancer Research
3. Rapid Phospho-Turnover by Receptor Tyrosine Kinases Impacts Downstream Signaling and Drug Binding
   Laura B. Kleiman, Thomas Maiwald, H. Conzelmann, Douglas A. Lauffenburger, Peter Karl Sorger · 2011 · Molecular Cell
4. Kinase Regulation by Hydrophobic Spine Assembly in Cancer
   Jiancheng Hu, Lalima Gagan Ahuja, Hiruy S. Meharena, Natarajan Kannan, Alexandr P. Kornev, Susan Serota Taylor, Andréy S. Shaw · 2014 · Molecular and Cellular Biology
5. EGF receptor in organ development, tissue homeostasis and regeneration
   Claudia Tito, Silvia Masciarelli, Gianni Colotti, Francesco Fazi · 2025 · Journal of Biomedical Science
6. Structural Basis for the Recognition of c-Src by Its Inactivator Csk
   Nicholas M. Levinson, Markus A. Seeliger, Philip A. Cole, John Kuriyan · 2008 · Cell
7. Signal Integration During Development: Mechanisms of EGFR and Notch Pathway Function and Cross-Talk
   David B. Doroquez, Ilaria Rebay · 2006 · Critical Reviews in Biochemistry and Molecular Biology
8. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
   Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, Feixiong Cheng · 2019 · PLoS Computational Biology
9. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
   Kurtis D. Davies, Sakshi Mahale, David P. Astling, Dara L. Aisner, Anh Tuan Le, Trista K. Hinz, Aria Vaishnavi, Paul A. Bunn, Lynn E. Heasley, Aik Choon Tan et al. · 2013 · PLoS ONE
10. A secretory kinase complex regulates extracellular protein phosphorylation
    Jixin Cui, Junyu Xiao, Vincent S. Tagliabracci, Jianzhong Wen, Meghdad Rahdar, Jack E. Dixon · 2015 · eLife
11. Structural Basis of AZD9291 Selectivity for EGFR T790M
    Xiao-E Yan, Pelin Ayaz, Sujie Zhu, Peng Zhao, Ling Liang, Casey H. Zhang, Ya-Chuang Wu, Je-Luen Li, Hwan Geun Choi, Xin Huang et al. · 2020 · Journal of Medicinal Chemistry
12. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
    Nichole E. M. Kaufman, Simran Dhingra, Seetharama D. S. Jois, M. Graça H. Vicente · 2021 · Molecules
13. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2
    Adelajda Zorba, Vanessa Buosi, S. Kutter, Nadja Kern, Francesco Pontiggia, Young-Jin Cho, Dorothee Kern · 2014 · eLife
14. EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
    Jean‐Nicolas Gallant, Jonathan H. Sheehan, Timothy M. Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally Jane York, Mark G. Kris, Jennifer A. Pietenpol et al. · 2015 · Cancer Discovery
15. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors
    Peng‐Cheng Lv, Changfang Zhou, Jin Chen, Penggang Liu, Kairui Wang, Wenjun Mao, Huan‐Qiu Li, Ying Yang, Jing Xiong, Hai‐Liang Zhu · 2009 · Bioorganic & Medicinal Chemistry
16. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
    Littlefield, Peter, Liu, Lijun, Mysore, Venkatesh, Shan, Yibing, Shaw, David E., Jura, Natalia · 2014 · Science Signaling
17. Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling
    Stephan Wilmes, Oliver Beutel, Zhi Li, Véronique François-Newton, Christian Paolo Richter, Dennis Janning, Cindy Kroll, Patrizia Hanhart, Katharina Hötte, Changjiang You et al. · 2015 · The Journal of Cell Biology
18. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
    Frosi, Yuri, Anastasi, Sergio, Ballarò, Costanza, Varsano, Giulia, Castellani, Loriana, Maspero, Elena, Polo, Simona, Alemà, Stefano, Segatto, Oreste · 2010 · Journal of Cell Biology
19. Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
    Thanyanan Reungwetwattana, Saravut John Weroha, Julian R. Molina · 2011 · Clinical Lung Cancer
20. Different Epidermal Growth Factor (EGF) Receptor Ligands Show Distinct Kinetics and Biased or Partial Agonism for Homodimer and Heterodimer Formation
    Jennifer L. Macdonald-Obermann, LINDA JOY PIKE · 2014 · Journal of Biological Chemistry
21. The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids
    George Hedger, Mark S.P. Sansom, Heidi Koldsø · 2015 · Scientific Reports
22. Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
    Ludi Yang, Ruobing Jia, Tongxin Ge, Shengfang Ge, Ai Zhuang, Peiwei Chai, Xianqun Fan · 2022 · Signal Transduction and Targeted Therapy
23. Hyaluronate—Epidermal Growth Factor Conjugate for Skin Wound Healing and Regeneration
    Hyemin Kim, Won Ho Kong, Keum‐Yong Seong, Dong Kyung Sung, Hyeonseon Jeong, Jin Kon Kim, Seung Yun Yang, Sei Kwang Hahn · 2016 · Biomacromolecules
24. Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay
    Wolfgang Jahnke, Robert M. Grotzfeld, Xavier Pellé, André Strauss, Gabriele Fendrich, Sandra W. Cowan‐Jacob, Simona Cotesta, Doriano Fabbro, Pascal Furet, Jürgen Mestan et al. · 2010 · Journal of the American Chemical Society
25. A Fence-like Coat for the Nuclear Pore Membrane
    Erik Debler, Yingli Ma, Hyuk‐Soo Seo, Kuo‐Chiang Hsia, Thomas R. Noriega, Günter Blobel, André Hoelz · 2008 · Molecular Cell
26. Dynamic Helix Interactions in Transmembrane Signaling
    Erin E. Matthews, Manuela A. Zoonens, Donald M. Engelman · 2006 · Cell
27. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases
    Haizhen A. Zhong, Ly M. Tran, Jenna L. Stang · 2009 · Journal of Molecular Graphics and Modelling
28. Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
    Shiqing Li, Paul H. Kussie, Kathryn M. Ferguson · 2008 · Structure
29. Unraveling structural mechanisms of allosteric drug action
    Nussinov, Ruth, Tsai, Chung-Jung · 2014 · Trends in Pharmacological Sciences
30. Asymmetric Tyrosine Kinase Arrangements in Activation or Autophosphorylation of Receptor Tyrosine Kinases
    Jae Hyun Bae, Joseph Schlessinger · 2010 · Molecules and Cells
31. A dynamically coupled allosteric network underlies binding cooperativity in Src kinase
    Zachariah H. Foda, Yibing Shan, Eric T. Kim, David Elliot Shaw, Markus A. Seeliger · 2015 · Nature Communications
32. The structure of CDK4/cyclin D3 has implications for models of CDK activation
    Tohru Takaki, Aude Echalier, Nick R. Brown, Tim Hunt, Jane Endicott, Martin E. M. Noble · 2009 · Proceedings of the National Academy of Sciences
33. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Cho, Jeonghee, Chen, Liang, Sangji, Naveen, Okabe, Takafumi, Yonesaka, Kimio, Francis, Joshua M., Flavin, Richard J., Johnson, William, Kwon, Jihyun, Yu, Soyoung et al. · 2013 · Cancer Research
34. The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications
    Jean L. Nakamura · 2007 · Expert Opinion on Therapeutic Targets
35. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases
    Edgar R. Wood, Lisa M. Shewchuk, Byron Ellis, Perry S. Brignola, Ronald L. Brashear, Thomas R. Caferro, Scott H. Dickerson, Hamilton D. Dickson, Kelly H. Donaldson, Michael D. Gaul et al. · 2008 · Proceedings of the National Academy of Sciences
36. The Design of Covalent Allosteric Drugs
    Nussinov, Ruth, Tsai, Chung-Jung · 2015 · Annual Review of Pharmacology and Toxicology
37. αC helix displacement as a general approach for allosteric modulation of protein kinases
    Lorenzo Palmieri, Giulio Rastelli · 2012 · Drug Discovery Today
38. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
    Xin Li, Yao‐Kuang Huang, Jing Jiang, Stuart J. Frank · 2008 · Cellular Signalling
39. Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling
    Ykelien L. Boersma, Ginger Chao, Daniel Steiner, Karl Dane Wittrup, Andreas Plückthun · 2011 · Journal of Biological Chemistry
40. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
41. A Rac-cGMP Signaling Pathway
    Dagang Guo, Ying-cai Tan, Dawei Wang, K. S. Madhusoodanan, Yi Zheng, Thomas Maack, J. Jillian Zhang, Xin‐Yun Huang · 2007 · Cell
42. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
    Helmout Modjtahedi, Byoung Chul Cho, Martin Christian Michel, Flavio Solca · 2014 · Naunyn-Schmiedeberg s Archives of Pharmacology
43. Recent progress on third generation covalent EGFR inhibitors
    Hengmiao Cheng, Sajiv K. Nair, Brion William Murray · 2016 · Bioorganic & Medicinal Chemistry Letters
44. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
    Nicolas Kiavué, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Céline Callens, Florence Lerebours, Jean‐Yves Pierga, François‐Clément Bidard · 2019 · Oncogene
45. Targeting EGFR in Lung Cancer: Current Standards and Developments
    Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
46. Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2
    2023
47. Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
    Valkov, Eugene, Sharpe, Tim, Marsh, May, Greive, Sandra, Hyvönen, Marko · 2011 · Topics in Current Chemistry
48. Ligand-Induced Structural Transitions in ErbB Receptor Extracellular Domains
    Jessica P. Dawson, Zimei Bu, Mark A. Lemmon · 2007 · Structure
49. Co-Occurring Gain-of-Function Mutations in HER2 and HER3 Modulate HER2/HER3 Activation, Breast Cancer Progression, and HER2 Inhibitor Sensitivity
    Ariella B. Hanker, Benjamin P. Brown, Jens Meiler, Arnaldo Marín, Harikrishna Sekar Jayanthan, Dan Ye, Chang-Ching A. Lin, Hiroaki Akamatsu, Kyung‐min Lee, Sumanta Chatterjee et al. · 2020 · Cancer Cell
50. Structure and Regulation of the Human Nek2 Centrosomal Kinase
    P. Rellos, Frank J. Ivins, Joanne E. Baxter, Ashley C. W. Pike, Timothy J. Nott, Donna-Marie Parkinson, Sanjan K. Das, Steven A. Howell, O. Fedorov, Qi Yu Shen et al. · 2006 · Journal of Biological Chemistry
51. Mechanisms of tumor resistance to EGFR-targeted therapies
    Elizabeth A. Hopper-Borge, Rochelle E. Nasto, Vladimir Ratushny, Louis M. Weiner, Erica A. Golemis, Igor A. Astsaturov · 2009 · Expert Opinion on Therapeutic Targets
52. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
    Benjamin P. Brown, Yunkai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller et al. · 2019 · Clinical Cancer Research
53. Protein–protein interactions in the allosteric regulation of protein kinases
    Patricia Pellicena, John Kuriyan · 2006 · Current Opinion in Structural Biology
54. Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor
    Tzipora Goldkorn, Simone Filosto, Samuel Chung · 2014 · Antioxidants and Redox Signaling
55. Ligand-induced EGF Receptor Oligomerization Is Kinase-dependent and Enhances Internalization
    Erik G. Hofman, Arjen N. Bader, Jarno Voortman, Dave J. van den Heuvel, Sara Sigismund, Arie J. Verkleij, Hans C. Gerritsen, Paul M.P. van Bergen en Henegouwen · 2010 · Journal of Biological Chemistry
56. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
    Ruth A. Mitchell, Rodney Brian Luwor, Antony Wilks Burgess · 2018 · Experimental Cell Research
57. Cancer driver mutations in protein kinase genes
    Ali Torkamani, Gennady M. Verkhivker, Nicholas J. Schork · 2008 · Cancer Letters
58. Receptor tyrosine kinase transmembrane domains
    Edwin Li, Kalina A. Hristova · 2010 · Cell Adhesion & Migration
59. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors
    Oreste Segatto, Sergio Anastasi, Stefano Alemà · 2011 · Journal of Cell Science
60. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
    Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca J. Nagy, Richard Burnham Lanman, Michael F. Berger, David Michael Hyman, David B. Solit et al. · 2017 · Cancer Discovery
61. Multisteric Regulation by Structural Disorder in Modular Signaling Proteins: An Extension of the Concept of Allostery
    Péter Tompa · 2013 · Chemical Reviews
62. Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells
    Imoh Sunday Okon, Kathleen A. Coughlan, Miao Zhang, Qiongxin Wang, Ming‐Hui Zou · 2015 · Journal of Biological Chemistry
63. Mechanistic insights into EGFR membrane clustering revealed by super-resolution imaging
    Jing Gao, Ye Wang, Mingjun Cai, Yangang Pan, Haijiao Xu, Junguang Jiang, Hongbin Ji, Hongda Wang · 2015 · Nanoscale
64. Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
    Richard L. Schroeder, C.L.K. Stevens, Jayalakshmi Sridhar · 2014 · Molecules
65. Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors
    Dries J.H. De Clercq, David E. Heppner, Ciric To, Jaebong Jang, Eunyoung Park, Cai‐Hong Yun, Mierzhati Mushajiang, Bo Hee Shin, Thomas W. Gero, David A. Scott et al. · 2019 · ACS Medicinal Chemistry Letters
66. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
    Silvia Mara Baez Rodriguez, A. El Kamel, Gheorghe Vasile Ciubotaru, Gelu Onose, Ani-Simona Sevastre, Veronica Sfredel, Suzana Dănoiu, Anica Dricu, Ligia Gabriela Tătăranu · 2023 · International Journal of Molecular Sciences
67. MAD contortions: conformational dimerization boosts spindle checkpoint signaling
    Marina Mapelli, Andrea Musacchio · 2007 · Current Opinion in Structural Biology
68. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks
    Sharmistha Chakraborty, Li Li, Vineshkumar Thidil Puliyappadamba, Gao Guo, Kimmo J. Hatanpaa, Bruce Mickey, Rhonda Frances Souza, Peggy Vo, Joachim Herz, Mei‐Ru Chen et al. · 2014 · Nature Communications
69. HER3 in cancer: from the bench to the bedside
    Lucía Gandullo‐Sánchez, Alberto Ocaña, Atanasio Pandiella · 2022 · Journal of Experimental & Clinical Cancer Research
70. Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications
    Darja Lavõgina, Erki Enkvist, Asko Uri · 2009 · ChemMedChem
71. The Chlamydia pneumoniae Invasin Protein Pmp21 Recruits the EGF Receptor for Host Cell Entry
    Katja Mölleken, Elisabeth Becker, Johannes H. Hegemann · 2013 · PLoS Pathogens
72. erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions
    Mara P. Steinkamp, Shalini T. Low-Nam, Shujie Yang, Keith A. Lidke, Diane S. Lidke, Bridget Smith Wilson · 2013 · Molecular and Cellular Biology
73. Tamoxifen resistance: From bench to bedside
    Marjolein Droog, Karin J. Beelen, Sabine C. Linn, Wilbert T. Zwart · 2013 · European Journal of Pharmacology
74. An electrostatic selection mechanism controls sequential kinase signaling downstream of the T cell receptor
    Neel H. Shah, Qi Wang, Qingrong Yan, Deepti Karandur, Theresa A. Kadlecek, Ian Fallahee, William P. Russ, Rama Ranganathan, Arthur Weiss, John Kuriyan · 2016 · eLife
75. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
    Lelais, Gérald, Epple, Robert, Marsilje, Thomas H., Long, Yun O., McNeill, Matthew, Chen, Bei, Lu, Wenshuo, Anumolu, Jaganmohan, Badiger, Sangamesh, Bursulaya, Badry et al. · 2016 · Journal of Medicinal Chemistry
76. Functional and Structural Stability of the Epidermal Growth Factor Receptor in Detergent Micelles and Phospholipid Nanodiscs
    Li-Zhi Mi, Michael J. Grey, N. Nishida, Thomas Walz, Chafen Lu, Timothy A. Springer · 2008 · Biochemistry
77. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
    Christopher C. Valley, Donna J. Arndt‐Jovin, Narain Karedla, Mara P. Steinkamp, Alexey I. Chizhik, William S. Hlavacek, Bridget Smith Wilson, Keith A. Lidke, Diane S. Lidke · 2015 · Molecular Biology of the Cell
78. Shape Transformable Strategies for Drug Delivery
    Wenfeng Jia, Yushan Wang, Rui Liu, Xiangrong Yu, Huile Gao · 2021 · Advanced Functional Materials
79. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor
    Yongjian Huang, Jana Ognjenović, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan · 2021 · eLife
80. Perspectives of HER2-targeting in gastric and esophageal cancer
    James Nathan Gerson, Sam Skariah, Crystal Shereen Denlinger, Igor A. Astsaturov · 2017 · Expert Opinion on Investigational Drugs
81. Direct and indirect cholesterol effects on membrane proteins with special focus on potassium channels
    Florina Zákány, Tamás Kovács, György Panyi, Zoltán Varga · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
82. Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
    Iván Plaza-Menacho, Luca Mologni, Neil Q. McDonald · 2014 · Cellular Signalling
83. Mechanistic insights into the activation of oncogenic forms of EGF receptor
    Zhihong Wang, Patti A. Longo, Mary Katherine Tarrant, Kwangsoo Kim, Sarah A. Head, Daniel J. Leahy, Philip A. Cole · 2011 · Nature Structural & Molecular Biology
84. Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation
    Ioannis E. Michailidis, Radda Rusinova, Anastasios Georgakopoulos, Yibang Chen, Ravi Iyengar, Nikolaos K. R K Robakis, Diomedes E. Logothetis, Lia Baki · 2010 · Pflügers Archiv - European Journal of Physiology
85. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
    Marisa L. Martin-Fernandez, David T. Clarke, Selene K. Roberts, Laura C. Zanetti-Domingues, Francesco Luigi Gervasio · 2019 · Cells
86. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
    David J. Riese, Richard M. Gallo, Jeffrey E. Settleman · 2007 · BioEssays
87. Monovalent and Multivalent Ligation of the B Cell Receptor Exhibit Differential Dependence upon Syk and Src Family Kinases
    Sayak Mukherjee, Jing W. Zhu, Julie Zikherman, Ramya Parameswaran, Theresa A. Kadlecek, Qi Wang, Byron B. Au‐Yeung, Hidde L. Ploegh, John Kuriyan, Jayajit Das et al. · 2013 · Science Signaling
88. Profile of neratinib and its potential in the treatment of breast cancer
    Anthony H. Kong, Katharina Feldinger · 2015 · Breast Cancer Targets and Therapy
89. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src
    Chung, Byung Min, Raja, Srikumar M, Clubb, Robert J, Tu, Chun, George, Manju, Band, Vimla, Band, Hamid · 2009 · BMC Cell Biology
90. Regulation of the catalytic activity of the EGF receptor
    Nicholas Endres, Kate Engel, Rahul Das, Erika Kovács, John Kuriyan · 2011 · Current Opinion in Structural Biology
91. Postsynaptic Clustering and Activation of Pyk2 by PSD-95
    Jason Alan Bartos, Jason D. Ulrich, Hongbin Li, Michael A. Beazely, Yucui Chen, John Ferguson MacDonald, Johannes Wilhelm Hell · 2010 · Journal of Neuroscience
92. The molecular basis of targeting protein kinases in cancer therapeutics
    Chung‐Jung Tsai, Ruth Nussinov · 2013 · Seminars in Cancer Biology
93. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma
    Andre Cassell, Jennifer Rubin Grandis · 2010 · Expert Opinion on Investigational Drugs
94. Protein-tyrosine kinase CAKβ/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 α2 helix and thus forming its dimer
    Takayuki Kohno, Eiko Matsuda, Hiroko Sasaki, Terukatsu Sasaki · 2008 · Biochemical Journal
95. Interdependent epidermal growth factor receptor signalling and trafficking
    Sylwia Jones, Joshua Zachary Rappoport · 2014 · The International Journal of Biochemistry & Cell Biology
96. Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
    Grit Sophie Herter-Sprie, Heidi E. Greulich, Kwok‐Kin Wong · 2013 · Frontiers in Oncology
97. The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers
    Laura C. Zanetti-Domingues, Dimitris Korovesis, Sarah R. Needham, Christopher J. Tynan, Shiori Sagawa, Selene K. Roberts, Antonija Kuzmanic, Elena Ortiz Zapater, Purvi Jain, Rob C. Roovers et al. · 2018 · Nature Communications
98. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
    Katharina Feldinger, Daniele Generali, Gabriela Krämer-Marek, Merel Gijsen, Tzi Bun Ng, Jack Ho Wong, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Jiliang Li et al. · 2014 · Oncotarget
99. ‘Latent drivers’ expand the cancer mutational landscape
    Ruth Nussinov, Chung‐Jung Tsai · 2015 · Current Opinion in Structural Biology
100. Prevalence and role of HER2 mutations in cancer
     Emiliano Cocco, Salvatore Lopez, Alessandro Davide Santin, Maurizio Scaltriti · 2019 · Pharmacology & Therapeutics